$ROIV
Roivant Sciences Ltd., a biopharmaceutical and healthcare technology company that researches and develops medicines. The company develops product candidates for the treatment of various therapeutics, including solid tumors, sickle cell diseases, hypophosphatasia, oncologic malignancies, psoriasis, atopic dermatitis, vitiligo, hyperhidrosis, acne, myasthenia gravis, warm autoimmune hemolytic anemia, thyroid eye diseases, sarcoidosis, and staph aureus bacteremia. The company was founded in 2014 and is based in London, the United Kingdom.
Healthcare
Sector
Biotechnology
Industry
Matthew Gline
CEO
908
Employees
$39.99
Current Price
$19.67B
Market Cap
Insider Activity Statistics
Aggregated buying and selling activity by time period
| Period | Type | Insiders | Transactions | Value | Shares | Buy/Sell Ratio |
|---|---|---|---|---|---|---|
| 1 week | Buys | 0 | 0 | - | - | All Sells |
| Sells | 2 | 6 | $20,090,346.26 | 487,943 | ||
| 2 weeks | Buys | 0 | 0 | - | - | All Sells |
| Sells | 2 | 7 | $27,352,346.26 | 687,943 | ||
| 1 month | Buys | 0 | 0 | - | - | All Sells |
| Sells | 2 | 10 | $41,693,013.78 | 1,087,943 | ||
| 2 months | Buys | 0 | 0 | - | - | All Sells |
| Sells | 4 | 17 | $50,057,256.64 | 1,315,743 | ||
| 3 months | Buys | 0 | 0 | - | - | All Sells |
| Sells | 5 | 26 | $85,719,561.75 | 2,292,566 | ||
See activity going back 12 months โ create a free account | ||||||
Insider Transactions
Recent purchases and sales by company insiders
| Date | Insider | Type | Shares | Price | Value | Actions |
|---|---|---|---|---|---|---|
| Nov 11, 2026 | Pulik Richard CFO | Sale | 45,195 | $41.47 | $1,874,236.65 | View Details |
| Nov 10, 2026 | Pulik Richard CFO | Sale | 125,000 | $41.20 | $5,150,000.00 | View Details |
| Nov 11, 2026 | Pulik Richard CFO | Sale | 47,635 | $41.89 | $1,995,430.15 | View Details |
| Nov 11, 2026 | Pulik Richard CFO | Sale | 82,170 | $42.03 | $3,453,605.10 | View Details |
| Nov 10, 2026 | Venker Eric President&Immunovant CEO | Sale | 158,194 | $40.44 | $6,397,365.36 | View Details |
| Nov 10, 2026 | Venker Eric President&Immunovant CEO | Sale | 29,749 | $41.00 | $1,219,709.00 | View Details |
| Nov 3, 2026 | Venker Eric President&Immunovant CEO | Sale | 200,000 | $36.31 | $7,262,000.00 | View Details |
| Oct 28, 2026 | Venker Eric President&Immunovant CEO | Sale | 200,000 | $36.59 | $7,318,000.00 | View Details |
| Oct 20, 2026 | Venker Eric President&Immunovant CEO | Sale | 14,144 | $35.42 | $500,980.48 | View Details |
| Oct 20, 2026 | Venker Eric President&Immunovant CEO | Sale | 185,856 | $35.09 | $6,521,687.04 | View Details |
| Oct 1, 2026 | Epperly Melissa B, Director | Sale | 16,850 | $36.08 | $607,948.00 | View Details |
| Oct 1, 2026 | Epperly Melissa B, Director | Sale | 900 | $36.57 | $32,913.00 | View Details |
| Sep 30, 2026 | Venker Eric President&Immunovant CEO | Sale | 200,000 | $36.62 | $7,324,000.00 | View Details |
| Sep 15, 2026 | Epperly Melissa B, Director | Sale | 4,338 | $39.65 | $172,001.70 | View Details |
| Sep 15, 2026 | Epperly Melissa B, Director | Sale | 600 | $40.38 | $24,228.00 | View Details |
| Sep 15, 2026 | Fitzgerald Meghan Director | Sale | 400 | $40.45 | $16,180.00 | View Details |
| Sep 15, 2026 | Fitzgerald Meghan Director | Sale | 4,712 | $39.68 | $186,972.16 | View Details |
| Sep 8, 2026 | Fitzgerald Meghan Director | Sale | 20,000 | $39.90 | $798,000.00 | View Details |
| Aug 28, 2026 | Venker Eric President&Immunovant CEO | Sale | 33,818 | $36.44 | $1,232,327.92 | View Details |
| Aug 28, 2026 | Venker Eric President&Immunovant CEO | Sale | 166,182 | $35.63 | $5,921,064.66 | View Details |
Upcoming Earnings
Scheduled earnings reports
No upcoming earnings scheduled
Past Earnings
Historical earnings results
EPS
Estimated-$0.37
Actual-$0.24
Beat
Revenue
Estimated$4.34M
Actual$35.12M
Beat
3 more earnings records available โ create a free account to see 12 months of history